US EditionPublished • loading... • Updated
Merck (MRK) stock price rises as Enflonsia approval and insider filing keep attention on what’s next
Summary by ts2.tech
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Merck (MRK) stock price rises as Enflonsia approval and insider filing keep attention on what’s next
New York, February 6, 2026, 11:57 EST — Regular session Merck & Co. shares rose 1.8% to $121.92 on Friday, after trading as high as $122.65 earlier in the session. The stock had opened at $121.01. The move came with a broad rebound across U.S. equities and healthcare, a pocket that tends to draw bids when risk appetite gets shaky. The SPDR S&P 500 ETF gained about 1.5% and the Health Care Select Sector SPDR was up about the same in midday tradin…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
